Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
Lee E, Burgess K. Altern Ther Health Med. 2025; 31(5):20–24.
No comparison group, so it cannot separate the treatment from placebo or natural recovery.
- Who or what was studied
- 2 adults (a 58-year-old man and a 68-year-old woman) at a private clinic in Florida, both of whom had received intravenous BPC-157 before
- Design
- Small open pilot study, IRB-approved
- Dose
- 10 mg on day 1 and 20 mg on day 2, each infused over one hour
- Duration
- 3 days
What it found
Blood tests of heart, liver, kidney, thyroid and blood-glucose markers showed no measurable change after the infusions, and no side effects were reported.
What it doesn't show
Two people over three days cannot establish that BPC-157 is safe, a limit the authors acknowledge by calling for further studies. Both participants had used the peptide before.
Funding and conflicts of interest
No funding or conflict-of-interest statement appears in the PubMed record. Check the full text.
Summary written from the study's abstract and checked against PubMed on November 9, 2026. How we check studies. Educational information, not medical advice.
Related studies
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine (Tewari et al., 2026)
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Mendias et al., 2026)
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (Vasireddi et al., 2025)
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (McGuire et al., 2025)